A Phase 3 interventional study of Ranibizumab in Retinopathy of Prematurity (ROP), sponsored by Novartis Pharmaceuticals. Completed at 73 sites in 24 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2023-02-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301 (NCT02375971)
This was a multicenter, open-label extension study where the Visual Acuity (VA) assessment at the child's 5th birthday visit was performed. The study had 2 distinct periods (Epochs). Treatment with study ranibizumab (either as retreatment after ranibizumab had already been injected in the same eye or as switch ranibizumab treatment from study laser therapy administered in the core study) was permitted for eligible eyes with recurrence/worsening of ROP up to and including Week 40 from the baseline visit in the core study (Epoch 1). The remainder of the extension study up to the 5th birthday visit (Epoch 2) was observational, with no study treatment planned to be administered.
In the core study, patients were randomized to 1 of the 3 treatment arms (ranibizumab 0.2 mg, ranibizumab 0.1 mg, and laser). Treatment arm assignment and patient identifier in the extension study remained the same as in the core study.
169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.
This study's enrollment of 180 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.
Browse Retinopathy of Prematurity studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Drug: Ranibizumab
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Drug: Ranibizumab
Laser therapy
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms
The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The better-seeing eye was defined as the eye with the higher ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the right eye was assigned as the better-seeing eye.
Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term
Number of participants with ocular AEs starting during the core study and ongoing at extension baseline, or starting on/after extension baseline were reported.
Time frame: throughout the study, approximately 5 years
Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term
Number of participants with non-ocular adverse events regardless of study treatment or procedure relationship (greater than or equal to 3% in any arm) by preferred term were reported.
Time frame: throughout the study, approximately 5 years
Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms
The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The worse-seeing eye was the eye with a lower ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the left eye was assigned as the worse-seeing eye.
Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 40 Weeks Post Core Baseline Visit
The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.
Time frame: at 40 weeks post core baseline visit
Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit
The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.
Time frame: at 52 weeks post core baseline visit
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
Time frame: at or before 40 weeks post baseline visit
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
Time frame: at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis
Time frame: at or before 40 weeks post baseline visit
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula
Time frame: at or before the participant's fifth birthday visit (up to maximum 5 years and 4 months post core baseline visit)
Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
Time frame: at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Number of Participants With Absence of Individual Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula
Time frame: at or before participant's 2 years corrected age visit (up to 2 years and 4 months post core baseline visit)
Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study
Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence.
Time frame: up to 40 weeks post baseline visit in the core study
Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study
Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. Beyond Week 40, participants did not receive any study intervention and no new data was collected after 40 weeks post core baseline visit.
Time frame: up to 52 weeks post baseline visit in the core study
Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period
Number of ranibizumab injections received in the treatment of participants with ROP up to and including 40 weeks post baseline visit in the core study were reported.
Time frame: up to and including 40 weeks post baseline visit in the core study
Refraction Status: Summary of Participants at Participant's 2 Years Corrected Age
Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years corrected age
Time frame: at participant's 2 years corrected age (maximum 2 years and 4 months post core baseline visit)
Refraction Status: Summary of Participants at the Participant's Fifth Birthday Visit
Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years' corrected age
Time frame: at the participant's fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Change From Baseline in Weight
Subject´s weight was reported to evaluate the physical development.
Time frame: Baseline of the core study, at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit) and at the subjects' fifth birthday (maximum 5 years and 4 months post core baseline visit)
Change From Baseline in Head Circumference
Subject´s head circumference was reported to evaluate the physical development.
Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Change From Baseline in Sitting Diastolic Blood Pressure
Subject´s Sitting Diastolic Blood Pressure was reported to evaluate the physical development.
Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Change From Baseline in Sitting Systolic Blood Pressure
Subject´s Sitting Systolic Blood Pressure was reported to evaluate the physical development.
Time frame: Baseline of the core study and at the subject's 2 years' corrected age (maximum 2 years and 4 months post core baseline visit)
Number of Participants With the Summary of Respiratory Function Status
Number of participants with respiratory function status was reported
Time frame: at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Number of Participants With Hearing Impairment of Any Type
Number of participants with hearing function status was reported
Time frame: at the participants' fifth birthday visit (maximum 5 years and 4 months post core baseline visit)
Duration of Hospitalization
Duration of hospitalization (from birth to first hospital discharge home) was reported to evaluate the health status of the subject
Time frame: From baseline of the core study up to 5 years and 4 months post core baseline visit
Weight at the Time of First Hospital Discharge
Weight (gram) at the time of first hospital discharge was reported to evaluate the health status of the subject
Time frame: From baseline of the core study up to 5 years and 4 months post core baseline visit
Study was carried out in Austria (2), Belgium (2), Croatia (1), Czech Republic (3), Denmark (1), Egypt (1), Estonia (1), France (2), Germany (1), Greece (3), Hungary (2), India (6), Italy (4), Japan (16), Lithuania (1), Malaysia (2), Romania (3), Russian Federation (5), Saudi Arabia (1), Slovakia (1), Taiwan (2), Turkey (3), United Kingdom (2), United States of America (9)
| Milestone | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Started | 61 | 65 | 54 |
| Completed | 60 | 65 | 53 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Withdrawal of informed consent | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Milestone | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Started | 60 | 65 | 53 |
| Completed | 54 | 55 | 47 |
| Not completed | 6 | 10 | 6 |
| Withdrew: Withdrawal of informed consent | 3 | 4 | 2 |
| Withdrew: Subject/guardian decision | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The better-seeing eye was defined as the eye with the higher ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the right eye was assigned as the better-seeing eye.
| Score on a scale | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms | 66.8 ± 1.95 | 64.6 ± 2.00 | 62.1 ± 2.18 |
Number of participants with ocular AEs starting during the core study and ongoing at extension baseline, or starting on/after extension baseline were reported.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship by Preferred Term | 19 | 26 | 22 |
Number of participants with non-ocular adverse events regardless of study treatment or procedure relationship (greater than or equal to 3% in any arm) by preferred term were reported.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Non-ocular Adverse Events (AEs) Regardless of Study Treatment or Procedure Relationship (Greater Than or Equal to 3% in Any Arm) by Preferred Term | 46 | 53 | 46 |
The VA assessment at the child's 5th birthday visit was performed using Early Treatment Diabetic Retinopathy Study (ETDRS) methodology. VA measurements were taken in a sitting position at an initial test distance of 3 meters using Lea Symbols charts. Scores represented the number of optotypes (Lea symbols) the participant identified and ranged from 0 to 100, with higher scores indicating better visual acuity. VA was tested in each eye, using the child's current refractive index. The worse-seeing eye was the eye with a lower ETDRS score at the 5th birthday visit. If both eyes had the same ETDRS score, then the left eye was assigned as the worse-seeing eye.
| Score on a scale | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Visual Acuity (VA) of the Worse-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms | 60.2 ± 2.95 | 53.8 ± 3.05 | 52.2 ± 3.30 |
The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Absence of active ROP at 40 weeks post core baseline visit | 55 | 58 | 46 |
| Absence of vessel dilatation | 55 | 58 | 46 |
| Absence of extra-retinal vessels | 57 | 59 | 47 |
The absence of active ROP in both eyes is defined by the absence of all of the following features: (1) Vessel dilatation of plus disease in at least 2 quardrants (some persisting tortuosity is allowed), (2) Extra-retina vessels extending from the retina into the vitreous and judged to be a sign of active ROP disease.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Absence of Active Retinopathy of Prematurity (ROP) at 52 Weeks Post Core Baseline Visit | 58 | 63 | 49 |
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Absence of All Ocular Structural Abnormalities at or Before 40 Weeks Post Baseline Visit | 59 | 61 | 47 |
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Absence of All Ocular Structural Abnormalities at or Before the Participant's Fifth Birthday Visit | 59 | 61 | 47 |
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Absence of substantial temporal retinal vessel | 59 | 63 | 49 |
| Absence of Retrolental membrane obscuring the view of the posterior pole | 60 | 65 | 53 |
| Absence of posterior retinal fold involving the macula | 59 | 65 | 51 |
| Absence of retinal detachment involving the macula | 60 | 63 | 51 |
| Absence of retinal detachment not involving the macula | 60 | 62 | 50 |
| Absence of pre-retinal fibrosis | 58 | 60 | 49 |
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Absence of temporal retinal vessel dragging | 59 | 63 | 49 |
| Absence of Retrolental membrane obscuring the view of the posterior pole | 60 | 65 | 52 |
| Absence of posterior retinal fold involving the macula | 59 | 65 | 51 |
| Absence of retinal detachment involving the macula | 60 | 63 | 50 |
| Absence of retinal detachment not involving the macula | 60 | 62 | 50 |
| Absence of pre-retinal fibrosis | 58 | 59 | 48 |
| Absence of optic disc pallor | 60 | 65 | 52 |
| Absence of optic disc swelling | 60 | 65 | 53 |
| Absence of pigmentary disturbance in the macula | 60 | 64 | 52 |
| Absence of atrophic changes in macula | 60 | 65 | 51 |
The absence of all ocular structural abnormalities is defined by the absence of all of the following fundus features in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Absence of All Ocular Structural Abnormalities at or Before Participant's 2 Years Corrected Age Visit | 59 | 61 | 47 |
Number of participants with absence of each structural abnormality in both eyes at or before the given time point: (1) Substantial temporal retinal vessel dragging causing abnormal structural features/macular Ectopia, (2) Retrolental membrane obscuring the view of the posterior pole, (3) Posterior retinal fold involving the macula, (4) Retinal detachment involving the macula, (5) Retinal detachment not involving the macula, (6) Pre-retinal fibrosis, (7) Optic disc pallor, (8) Optic disc swelling, (9) Pigmentary disturbance in the macula, (10) Atrophic changes in the macula
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Absence of substantial temporal retinal vessel dragging | 59 | 63 | 49 |
| Absence of Retrolental membrane obscuring the view of the posterior pole | 60 | 65 | 52 |
| Absence of posterior retinal fold involving the macula | 59 | 65 | 51 |
| Absence of retinal detachment involving the macula | 60 | 63 | 50 |
| Absence of retinal detachment not involving the macula | 60 | 62 | 50 |
| Absence of pre-retinal fibrosis | 58 | 59 | 48 |
| Absence of optic disc pallor | 60 | 65 | 53 |
| Absence of optic disc swelling | 60 | 65 | 53 |
| Absence of pigmentary disturbance in the macula | 60 | 64 | 52 |
| Absence of atrophic changes in macula | 60 | 65 | 52 |
Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Recurrence of ROP up to 40 Weeks Post Baseline Visit in the Core Study | 19 | 22 | 11 |
Recurrence of ROP was defined as ROP receiving any post-baseline intervention after the 1st study treatment in the core study. In the ranibizumab arms, post-baseline interventions were ranibizumab retreatment or switch to laser. In the laser arm, post-baseline interventions were supplementary laser treatments after 11 days post-baseline, or switch to ranibizumab; supplementary laser treatment within 11 days post-baseline was not counted as recurrence. Beyond Week 40, participants did not receive any study intervention and no new data was collected after 40 weeks post core baseline visit.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Recurrence of ROP up to 52 Weeks Post Baseline Visit in the Core Study | 19 | 22 | 11 |
Number of ranibizumab injections received in the treatment of participants with ROP up to and including 40 weeks post baseline visit in the core study were reported.
| Number of injections | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Ranibizumab Injections Received Per Participant Over the Whole Safety Observation Period | 2.5 ± 0.96 | 2.5 ± 1.06 | 2.4 ± 0.92 |
Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years corrected age
| diopters | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Best eye | -0.697 ± 2.7032 | -0.713 ± 2.6100 | -1.793 ± 4.1570 |
| Worst eye | -0.825 ± 2.6575 | -0.829 ± 2.8346 | -1.516 ± 3.5652 |
Summary of participants was reported to evaluate the refraction in each eye at the participant's 2 years' corrected age
| diopters | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Best eye | -0.601 ± 2.8107 | -0.859 ± 2.7406 | -1.883 ± 4.4970 |
| Worst eye | -0.904 ± 2.8501 | -1.074 ± 3.0405 | -1.706 ± 3.5740 |
Subject´s weight was reported to evaluate the physical development.
| grams | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Year 2 | 8695.9 ± 1406.58 | 8461.7 ± 1375.95 | 8840.6 ± 1643.80 |
| 5th Birthday | 14611.9 ± 3018.65 | 14324.7 ± 2616.96 | 14689.4 ± 3300.05 |
Subject´s head circumference was reported to evaluate the physical development.
| cm | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Change From Baseline in Head Circumference | 16.5 ± 2.60 | 16.2 ± 2.78 | 17.2 ± 2.81 |
Subject´s Sitting Diastolic Blood Pressure was reported to evaluate the physical development.
| mmHg | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure | 16.7 ± 14.92 | 13.6 ± 14.10 | 16.5 ± 12.14 |
Subject´s Sitting Systolic Blood Pressure was reported to evaluate the physical development.
| mmHg | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure | 20.6 ± 16.13 | 16.2 ± 15.95 | 17.6 ± 12.75 |
Number of participants with respiratory function status was reported
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of participants with Wheezing/whistling status | 6 | 4 | 2 |
| Number of participants with attacks of wheezing | 47 | 50 | 45 |
| Number of participants with frequency of sleep disturbance due to wheezing | 47 | 52 | 47 |
| Number of participants with presence of wheezing limiting child's speech ability | 1 | 0 | 0 |
| Number of participants with dry cough status at night | 5 | 2 | 1 |
| Number of participants with presence of smoker at home | 15 | 8 | 4 |
Number of participants with hearing function status was reported
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants With Hearing Impairment of Any Type | 2 | 2 | 4 |
Duration of hospitalization (from birth to first hospital discharge home) was reported to evaluate the health status of the subject
| days | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Duration of Hospitalization | 111.1 ± 62.27 | 116.2 ± 78.10 | 95.7 ± 57.07 |
Weight (gram) at the time of first hospital discharge was reported to evaluate the health status of the subject
| gram | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Weight at the Time of First Hospital Discharge | 2910.9 ± 1359.34 | 2966.5 ± 1198.60 | 2658.7 ± 926.92 |
Collected over throughout the study, up to approximately 5 years. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.2 mg | 0/61 (0%) | 21/61 (34.4%) | 41/61 (67.2%) |
| Ranibizumab 0.1 mg | 0/65 (0%) | 27/65 (41.5%) | 46/65 (70.8%) |
| Laser Therapy | 2/54 (3.7%) | 26/54 (48.1%) | 40/54 (74.1%) |
| Total | 2/180 (1.1%) | 74/180 (41.1%) | 127/180 (70.6%) |
| Event | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| BronchitisInfections and infestations | 3/61 | 3/65 | 5/54 | 11/180 |
| PneumoniaInfections and infestations | 2/61 | 4/65 | 4/54 | 10/180 |
| BronchiolitisInfections and infestations | 4/61 | 3/65 | 0/54 | 7/180 |
| PyrexiaGeneral disorders | 3/61 | 1/65 | 2/54 | 6/180 |
| DehydrationMetabolism and nutrition disorders | 3/61 | 0/65 | 1/54 | 4/180 |
| VomitingGastrointestinal disorders | 1/61 | 3/65 | 2/54 | 6/180 |
| Febrile convulsionNervous system disorders | 2/61 | 3/65 | 0/54 | 5/180 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/61 | 3/65 | 2/54 | 6/180 |
| GastroenteritisInfections and infestations | 1/61 | 0/65 | 2/54 | 3/180 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 1/61 | 1/65 | 2/54 | 4/180 |
| Event | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| StrabismusEye disorders | 10/61 | 12/65 | 12/54 | 34/180 |
| PyrexiaGeneral disorders | 6/61 | 11/65 | 10/54 | 27/180 |
| NasopharyngitisInfections and infestations | 11/61 | 11/65 | 9/54 | 31/180 |
| ConstipationGastrointestinal disorders | 4/61 | 8/65 | 2/54 | 14/180 |
| Otitis mediaInfections and infestations | 7/61 | 2/65 | 3/54 | 12/180 |
| BronchitisInfections and infestations | 4/61 | 4/65 | 6/54 | 14/180 |
| MyopiaEye disorders | 6/61 | 3/65 | 5/54 | 14/180 |
| DiarrhoeaGastrointestinal disorders | 3/61 | 5/65 | 5/54 | 13/180 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/61 | 4/65 | 5/54 | 13/180 |
| PharyngitisInfections and infestations | 2/61 | 3/65 | 5/54 | 10/180 |
| Age, Continuous(Weeks) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| Mean | 38.88 ± 7.316 | 40.16 ± 9.836 | 37.48 ± 8.745 | 38.92 ± 8.739 |
| Sex: Female, Male(Participants) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| Female | 32 | 35 | 27 | 94 |
| Male | 29 | 30 | 27 | 86 |
| Race/Ethnicity, Customized(Participants) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| Caucasian | 38 | 40 | 32 | 110 |
| Black | 0 | 4 | 2 | 6 |
| Asian | 22 | 18 | 18 | 58 |
| Native American | 0 | 0 | 0 | 0 |
| Pacific Islander | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 |
| Other | 1 | 3 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Apr 2022, 70 months.
Results were first posted in Feb 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab